Ongentys® (opicapone) – New drug approval
April 27, 2020 - Neurocrine Biosciences announced the FDA approval of Ongentys (opicapone), as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
Download PDF
